Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00862459 · ClinicalTrials.gov registry record · Phase 2
Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 237
- Enrollment target
NCT00862459 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 237 participants.
The verdict
NCT00862459, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 237 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine. The results of the MRI with Gadavist Injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with OptiMARK.
Interventions
- DRUG Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
- DRUG Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
- DRUG Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)
- DRUG OptiMARK~0.1 mmol/kg BW
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00862459
The ClinicalTrials.gov registry entry for NCT00862459 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 237 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875) is the first listed.
NCT00862459 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00862459 about?
NCT00862459 is a clinical study titled "Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)". The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of Gadavist when used for taking images of the brain and spine. The results of the MRI with Gadavist Injection will be compared to the results of MR images taken without contrast and w...
What is the current status of trial NCT00862459?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 237 participants. The study started on 2005-08. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00862459?
The interventions under investigation include: Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875) (DRUG), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875) (DRUG), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875) (DRUG), OptiMARK~0.1 mmol/kg BW (DRUG).
Who is sponsoring clinical trial NCT00862459?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.